Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevifibatide citrate injection in endovascular thrombectomy for acute large-vessel occlusive stroke
ChiCTR2500110790Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of the University of South China
- Start
- Oct 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bevifibatide in ischemic stroke, sponsored by The First Affiliated Hospital of the University of South China. Primary endpoints: Incidence of symptomatic intracranial hemorrhage (sICH) within 48 hours and Favorable functional outcome at 90 days (mRS 0–2). Planned start Oct 2025; status: not yet recruiting.
02
Drugs
bevifibatide
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2500110790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110790.